Renaissance Technologies LLC Has $9.87 Million Position in GeneDx Holdings Corp. $WGS

Renaissance Technologies LLC raised its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 168.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,716 shares of the company’s stock after purchasing an additional 96,400 shares during the period. Renaissance Technologies LLC’s holdings in GeneDx were worth $9,872,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new position in GeneDx during the 4th quarter worth $27,000. Fifth Third Bancorp acquired a new position in shares of GeneDx in the 1st quarter valued at approximately $31,000. Quarry LP raised its position in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares in the last quarter. Ramirez Asset Management Inc. bought a new stake in shares of GeneDx during the 4th quarter worth $33,000. Finally, Greenline Wealth Management LLC bought a new position in shares of GeneDx in the fourth quarter worth about $33,000. Institutional investors own 61.72% of the company’s stock.

Insider Activity

In other news, CFO Kevin Feeley sold 3,729 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total value of $226,611.33. Following the completion of the transaction, the chief financial officer directly owned 39,954 shares in the company, valued at approximately $2,428,004.58. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister purchased 46,273 shares of GeneDx stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the completion of the transaction, the director directly owned 4,784,570 shares of the company’s stock, valued at approximately $186,167,618.70. The trade was a 0.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th. Wall Street Zen cut shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Craig Hallum reiterated a “buy” rating and set a $85.00 price objective on shares of GeneDx in a report on Tuesday, May 5th. Finally, BTIG Research lowered their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $87.43.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Zacks Research upgraded GeneDx from “strong sell” to “hold,” indicating a less bearish view of the shares, although the rating does not represent a bullish recommendation. Zacks.com
• Neutral Sentiment: The numerous announcements largely repeat the same legal notice: investors who purchased GeneDx shares between April 16, 2025, and May 4, 2026, may apply to lead the lawsuit by August 3. The notices are investor-solicitation releases rather than new operational or financial developments. Rosen Law Firm deadline notice
• Negative Sentiment: Several firms, including Hagens Berman, Rosen Law Firm, Robbins Geller, Bragar Eagel & Squire, and others, confirmed or promoted a securities-fraud class action against GeneDx. The lawsuit alleges violations of federal securities laws and claims that the company made misleading statements regarding acquisition performance and related business prospects. Hagens Berman class action notice
• Negative Sentiment: One notice links the allegations to an asserted 49% stock decline, citing a reported $51 million acquisition expectation followed by a $31.2 million write-off within roughly 12 months. These allegations have not been proven in court, but the litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. Kahn Swick and Foti class action notice

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $65.11 on Monday. The company’s 50-day moving average is $60.67 and its 200 day moving average is $69.59. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a market capitalization of $1.93 billion, a P/E ratio of -24.29 and a beta of 1.92.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the previous year, the company posted ($0.23) earnings per share. On average, equities research analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.